Fatty liver : current look at the old disease by unknown
Review Article
209
Fatty liver Ñ current look at the old disease
Tomasz Mach
Chair and Department of Infectious Diseases, Collegium Medicum, Jagiellonian University, Cracow, Poland
key words: fatty liver, alcoholism, obesity, diabetes mellitus, lipids, metabolism
SUMMARY
The report is devoted to the presentation of aetiological factors causing fatty liver, including alcohol, obesity,
diabetes mellitus, hyperlipoproteinaemias and drugs. The author discusses morphological changes typical for
the fatty liver such as large or small fatty droplets in hepatocytes and rarely coexisting hepatitis (so-called steato-
hepatitis). The work presents symptoms, changes in biochemical analyses of serum as well as methods of the
liver visualisation used in the diagnostics of fatty liver. The treatment in based on the elimination of aetiological
factors and properly balanced diet with support of pharmacotherapy in selected cases.
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Fatty liver (steatosis; FL) is defined when fat, mainly
triglycerides (TG), exceeds 5% of the liver weight
[1]. According to the other description, it is an
accumulation of fat droplets in over half of hepato-
cytes. FL is a morphological description of the sta-
tus of the liver parenchyma and it represents the
organ response to different noxious factors. Normal
liver contains small fat droplets in hepatocytes,
however they are seen only in the electron micro-
scopic studies.
Etiopathogenesis. The factors responsible for the
development of disturbances in lipid metabolism
of the liver are presented in Table 1.
Pathomechanism of FL is still not fully discovered.
The liver plays a central role in the lipid metabo-
lism. It takes up free fatty acids (FFA) derived from
the chylomicrons which transport dietary fat
absorbed from the intestine and FFA liberated from
adipose tissue. A part of FFA is oxidised to CO2 or
ketone bodies in the hepatocyte mitochondria and
the majority is incorporated in composed lipids,
i.e. TG, phospholipids and cholesterol esters [1—4].
FFA are also synthesised de novo in the hepatocyte
[1,4,5]. TG packed with apoproteins, phospho-
lipids and cholesterol are exported from liver cell
as very low density lipoproteins (VLDL; [1,4,5]).
Lipoproteins are synthesised and degraded in the
liver and chylomicrons; low density lipoproteins
(LDL) and high density lipoproteins (HDL) are
catabolised in hepatocytes as well [1,2,4,5].
Theoretically, FL could accumulate through at least
four mechanisms:
1. increased delivery of dietary fat absorbed from
the small intestine. Fat incorporated into chy-
lomicrons enters the circulation and is transport-
ed to the liver. Moreover, FFA are mobilised
from adipose tissue by alcohol, corticosteroids
and in diabetics;
2. increased amount of FFA caused by increased
synthesis or decreased degradation by oxidation
in mitochondria;
3. decreased export of TG from hepatocytes.
Failure of apoprotein synthesis leads to difficulty
in export of TG as VLDL and hence FL [1]. This
is an important pathogenic factor in the devel-
opment of FL under influence of toxic sub-
stances (CCl4, yellow phosphorus, etionine),
some drugs (antibiotics, tetracyclines inhibiting
protein production), low protein diet, exudative
enteropathy or protein-caloric malnutrition
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(kwashiorkor; [1—3,5]). In some patients with FL,
genetically dependent increased synthesis of apoB-
MRNA was shown, which decreases production of
apoprotein B in hepatocytes [6];
4. increased flow of carbohydrates into the liver,
which are metabolised to the FFA (e.g. in dia-
betes mellitus; [1—5]).
The role of hepatic lipocytes, called Ito cells, in
accumulation of lipids in the liver is still not fully
established. The multiplication and enlargement of
these cells are observed under influence of glyco-
corticosteroids, alcohol and prolonged administra-
tion of low-magnesium diet [2].
Many drugs can cause FL. Hepatocellular injury is
usually due to a toxic metabolite of the drug. This
follows exhaustion of intracellular substances such
as glutathione. The free radicals produced by
oxidative reactions of cytochrome P450 bind to
proteins and to unsaturated fatty acids of cell
membrane. This results in lipid peroxidation and
membrane damage. The final outcome is hepato-
cyte death related to failure to pump calcium from
the cytosol and to depressed mitochondrial func-
tion. The greatest necrosis is observed in central
areas of the liver acinus (so-called zone 3), where
drug metabolising enzymes are found in the high-
est concentration and where the oxygen tension is
lowest in sinusoidal blood [1]. Fatty change is also
seen in hepatocytes but inflammatory reaction is
slight [1].
The main etiologic factors causing FL are alcohol,
obesity, diabetes mellitus and hyperlipopro-
teinaemias [7]. Chronic alcoholism is the main eti-
ologic factor in FL in countries with large alcohol
consumption, but a degree of the liver changes is
proportional to the time and amount of drinking
[1,4,8].
Ethanol oxidation takes place in the hepatocyte
cytosol. The acetaldehyde produced may be injuri-
ous in mitochondria and cytosol, causing mem-
brane damage and cell necrosis [1]. Alcohol causes
accumulation of lipids in hepatocytes through
many mechanisms. It is know as a pure hepatotox-
in to the liver cell damaging mitochondria and
leading to the absence of ergastoplasm and focal
degradation of cytoplasm. Alcohol is a high caloric
compound (so-called empty calories) with easy oxi-
dation in the hepatocytes, where it exchanges the
residual carbohydrates [8,9].
In chronic alcoholism, FL is developed as a conse-
quence of increased production and decreased
oxidation of FFA in hepatic mitochondria, as well
as a result of peripheral lipolysis of adipose tissue
and increased flow of FFA into the liver [1,4,9-11].
In alcoholic FL, decreased amount of glutation in
hepatocytes is observed. It leads to disturbances in
detoxification processes [11,12]. Some significance
is also ascribed to the disturbances in nutrition of
the alcoholics. Nutritional factors are important,
because the consumption of a meal rich in ener-
getic products (carbohydrates and fat) and without
proper amount of protein, can be a cause of FL,
even in non-drinkers [8,9].
The important role in the pathogenesis of FL, par-
ticularly caused by alcohol and drugs, is played by
the direct hepatocellular necrosis by free radicals
and lipid peroxidation products with subsequent
membrane damage [1]. It was shown in experi-
mental studies that alcohol induces lipid peroxida-
tion as a result of increased acetaldehyde and free
oxygen radicals production [1,2,11]. Lipid peroxi-
dation causes oxidation of pyridine nucleotides,
accumulation of calcium anions, disturbed of func-
1. Toxic factors:
¥ alcohol
¥ drugs (corticosteroids, methotrexate, 5-fluorouracyl, valproic
acid, amiodarone, nifedipine, high doses of tetracyclines,
oestrogens and vitamin A)




¥ bad eating (over-eating or protein-caloric malnutrition, kwash-
iorkor, diet with improper proportion of aminoacids choline and
methionine)
¥ pancreatic disease
¥ total parenteral nutrition (TPN)
¥ jenuno-ileal bypass
3. Endocrine factors and metabolic diseases:
¥ diabetes mellitus
¥ primary and secondary hyperlipidaemias
¥ acute fatty liver of pregnancy
¥ early stages of WilsonÕs disease and hemochromatosis
¥ abetalipoproteinaemia, glycogenoses, galactosaemia, choles-
terol esters storage disease, genetic defects of mitochondrial
fatty acids oxidation
4. Other rare causes:
¥ chronic inflammatory bowel disease
¥ exudative enteropathy
¥ ReyeÕs syndrome
Table 1. The aetiology of fatty liver.
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tion of many reticulum endoplasmic enzymes,
release of hydrolytic enzymes from lysosomes,
diminution of cell membrane fluidity, and finally,
the damage of the liver cells [2]. Studies in vivo
and in vitro in isolated hepatocytes showed, that
lipid peroxidation disturbs lipoprotein excretion
mainly on the level of their liberation from Golgi
apparatus and with other toxic factors it leads to
hepatocytes damage and accumulation of lipids
inside them [13]. Lipid peroxidation not only indi-
cates the degree of the cell damage, but it may also
play a role in pathogenesis of FL, fibrosis and liver
cirrhosis, through the damage of cell membrane
and increased collagen production [11].
In alcoholic FL, the fat accumulates in centrizonal
and midzone of the liver acinus (zones 3 and 2)
[1]. In the more severely affected, the fatty change
is diffuse. The fat may be in macrovesicular (large
droplet) form. Less often, it is in microvesicular
(small droplet) form. Microvesicular fat represents
mitochondrial damage and more active lipid syn-
thesis by the hepatocyte [1].
In alcoholic FL large fat droplets appear in the
hepatocytes, dislocate cell nucleus and enlarge
liver acinus [1,9]. In chronic alcoholism we can dis-
tinguish not only FL but also other morphological
changes of the liver: acute alcoholic hepatitis
(steatohepatitis, i.e. FL with necrosis of hepato-
cytes, inflammatory inflitrations with neutrophils
mainly, sclerosing hyaline necrosis with collagen
deposition in the central area of acinus, Mallory‘s
hyaline, enlarged (giant) mitochondria and fre-
quently cholestasis), liver fibrosis (particularly in the
region of central vein) and liver cirrhosis
[1,3,8,9,14].
The patients with alcoholic FL are usually asympto-
matic, sometimes with pain in liver region,
enlarged and smooth liver. Liver function tests may
be normal or transaminases and alkaline phos-
phatase are increased [1,3,4,15]
Alcoholic FL stops usually in the course of 4-8
weeks after discontinuation of drinking and the
treatment is not necessary [3,4]. Until now, this
disease was recognised as a mild pathology with a
slight risk of the development of liver cirrhosis.
Numerous observations of persons who continue
drinking alcohol lead to the opinion that there is a
risk of liver changes progression and possible
development of liver cirrhosis in 10% of cases and
liver fibrosis in 8% of cases after 10 years [16].
According to Teli et al, there are the indices of the
histological progression of the liver damage like
mixed small and large droplets fatty infiltrations
and the presence of large mitochondria [16].
Obesity is the main non-alcoholic cause of FL
[1,4,5,9,10,17]. The degree of steatosis correlates
with the increase in body weight in both adults and
children [1]. It is showed in increased lipolysis from
the well developed adipose tissue and more FFA
are supplied to the liver. This leads to an imbal-
ance between TG synthesis and their secretion
from the liver. There is also an imbalance between
protein and calorie intake [1].
The study on the large number of obese persons
showed the presence of FL in 91% of cases and
steatohepatitis in 14% of cases [5]. Japanese studies
on the large population of middle-aged people
showed with the help of ultrasound (USG) that FL
accompanies obesity in 18—24% of cases [18].
Body mass index, liver enzymes, TG, cholesterol
and glucose in blood serum were higher in men
with FL then in persons without FL. FL usually
stops after administration of low-calorie diet and
reduction of body mass [1,4].
The frequent cause of FL, particularly in obese per-
son, are disturbances of lipid metabolism [1].
Retrospective analysis of patients with this changes
and histologically confirmed liver damage showed
different degree of hepatic injury from simple FL,
FL with hepatitis (steatohepatitis) and FL with liver
fibrosis or cirrhosis [19,20]. In patients with steato-
sis affecting over 60% hepatocytes, the TG serum
level was double when compared with the group
with less accumulated fat. In patients with steato-
hepatitis, TG level was twice higher than in
patients with FL and liver fibrosis; these patients
also had a significantly lower level of HDL [19,20].
The study on the correlation between FL diag-
nosed by USG and the disturbances in lipid metab-
olism in obese people showed the presence of FL
in 17% of cases with hypercholesterolaemia and in
50% of cases with mixed hyperlipidaemias (total
cholesterol was over 200 mg% and TG over 2, 3
mmol/l). The patients with mixed hyperlipidaemia
and FL had TG twice higher and HDL lower in
comparison to patients without FL [19,20].
Type 2 diabetes mellitus, particularly in obese and
improperly treated subjects, is a common cause of
FL [1,4,7,10]. Diabetes is marked by insulin defi-
ciency and glucagon excess. This enhances lipolysis
and inhibits glucose uptake thus increasing TG for-
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mation by adipose tissue [1]. There are noticed dis-
turbances of FFA metabolism in the liver and
increased their release from the adipose tissue in
diabetics [1,4,10]. Changes in oxidative phospho-
rylation in mitochondria, glucose metabolism with
subsequent decrease of ATP level in hepatocytes,
and disturbed binding of TG with apoproteins and
their excretion from the liver are also seen in dia-
betics [5,21].
FL can develop in about 25-100% of patients given
long term total parenteral nutrition (TPN). The
increased transaminases, alkaline phosphatase and
bilirubin values in blood serum (following approxi-
mately 2 weeks of treatment) are the main symp-
toms of FL in these cases [3,9,22]. Hepatic fatty
change occurs partially with high glucose or other
carbohydrates feeding when the rate of infusion
exceeds the hepatic oxidative capacity so that fat is
synthesised [1]. Choline deficiency plays a partial
role in FL development [23,24]. It is recommended
to maintain appropriate balance of TPN and
choline or lecithin supplementation. FL is com-
pletely reversible, however the continuation of
improperly prepared TPN can lead to the develop-
ment of more pronounced hepatic lesions (e.g.
steatohepatitis) [22,24].
Acute FL of pregnancy is a very severe disease and
appears in every 6-13 thousands of pregnancies
[1,3,9,25,26]. Its pathogenesis is not completely
known. According to Sherlock, this disease belongs
to the so-called mitochondrial cyto-pathies, which
include ReyÕe syndrome, some genetic defects,
and rug caused dysfunction of these organelles [1].
In acute FL of pregnancy, there is inhibition of FFA
beta-oxidation in hepatocytes mitochondria [1,3].
In most cases, nausea, vomiting, abdominal pain or
jaundice appear during the third trimester of preg-
nancy. Biochemical tests show increased bilirubin
and transaminases, prolonged prothrombin time
and frequently, the syndrome of disseminated
intravascular coagulation [3,4,26]. The diagnosis is
based on the liver biopsy, which shows small
droplet FL, necrosis of hepatocytes and deposits of
fibrin in sinusoids [1,3,4,25]. The disease resolves
usually after the delivery, therefore, the induction
of delivery is the first-choice treatment; liver trans-
plantation is rarely necessary [1,3,26].
Improper alimentation is another cause of FL. This
disease is frequently seen in children with chronic
protein-low alimentation in some tropical coun-
tries, in Africa, Asia and South America [1,4]. The
liver changes in kwashiorkor are accompanied by
other symptoms, like starvation anasarca or distur-
bances in consciousness [1,4,7,27]. FL in these
cases resolves rather slowly as a result of diet rich
in protein [27].
The diet short of choline can also cause FL [23].
Choline is necessary in phosopholipids production,
which are the components of cellular membranes;
it also participates in acetylcholine biosynthesis and
is the source of methyl groups in the organism
[23,24]. Lack of choline disturbs synthesis of phos-
phatydylcholine which is necessary in the secretion
of VLDL from the liver [24].
Not fully explained role in the development of FL
in some diseases (ReyeÕs syndrome, lipid store dis-
eases) is played by the disturbances of intracellular
transport of FFA, caused by increased amount of
fatty acid binding protein [14].
Morphology. FL is a histopathological entity.
Increased accumulation of fat in the liver is divided
into two morphological categories: macroscopic
(large droplet, macrovesicular) and microscopic
(small droplet; microvesicular) [1,3,4,15,25,28].
In macrovesicular FL, the hepatocytes are with
punched out, empty vacuoles, and with the nucle-
us displaced to the periphery of the cell [1]. These
changes are caused by the accumulation of fat
containing vacuoles in the cell. It may be mostly
found in alcohol, type II diabetes mellitus, obesity,
protein calorie malnutrition, treatment with corti-
costeroids, high dose oestrogens, TPN, amio-
darone, methotrexate and other toxic states (Table
1; [1,3,4]). These changes are frequently reversible,
but only when etiologic factor is no longer active.
In microvesicular FL, small lipid droplets are pre-
sented in hepatocytes cytoplasm and mostly they
do not dislocate the nucleus. Cell necrosis is vari-
able and inconsiderable, there may occasionally be
massive necrosis particularly in central area of aci-
nus (zone 3) [1]. Histological examination of the
liver shows hepatocytes with foamy cytoplasm and
central nucleus [1,25,28]. The microvesicular FL
can be related to a widespread hepatic metabolic
disturbance, particularly involving mitochondria
[1]. The most frequent causes are acute FL of preg-
nancy, Reye‘s syndrome, hepatotoxic drugs (sodi-
um valproate, large doses of tetracyclines), as well
as less frequently alcohol and genetic defects of
mitochondrial FFA beta-oxidation [1,4,25,28]. The
onset of these diseases varies and in most
instances, it remains obscure. Microvesicular FL is
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frequently responsible for severe hepatic failure
and multiorgan complications [1].
If we consider as a basis of histological analysis of
the liver acinus, as the smallest functional part of
the liver according to Rappaport, the lipid droplets
can accumulate in periportal areas (zone 1), in aci-
nar centre adjacent to terminal hepatic vein (zone
3) or in the whole acinus [1]. Steatosis is present
most frequently in the middle of acinus, in zone 3,
which is the microcirculatory periphery susceptible
to many noxious factors [1,3,25,27].
FL may be either diffuse or focal. In the majority of
clinical cases, diffuse FL is observed. Focal FL is
recognised with USG, when areas of increased
echogenicity, mostly located under the Glisson‘s
capsule, are seen in approx. 9—22% of cases [1]. It
should be distinguished from other focal changes of
the liver by the thin-needle aspiration biopsy under
USG or CT guidance. The focal fat lesions are usu-
ally multiple and resolve with time, they may be
seen in diabetics, alcoholics, the obese persons,
those on TPN and with CushingÕs syndrome [1,15].
The histological changes of the liver in patients with
FL may be accompanied by inflammatory infiltra-
tions (steatohepatitis), fibrosis or cirrhosis [1,3,4,9].
On the basis of aetiology, steatohepatitis may be
alcoholic or non-alcoholic, and the histology of the
liver may be similar in both groups with large or
small droplets steatosis, inflammation, necrosis of
hepatocytes, Mallory bodies, fibrosis [29—31].
Non-alcoholic steatohepatitis (NASH) is observed
mainly in obesity (18% of cases according. to
autopsy studies), several times more frequently in
middle-age women with diabetes mellitus and
hyperlipidaemia, moreover Ñ in patients with thy-
roid insufficiency, jejuno-ileal bypass operations in
obesity, in drug toxicity (e.g. amiodarone), TPN
[1,13,17,29—31]. The aetiology of NASH is
obscure. The great importance is associated with
the hepatic damage related to lipid peroxidation
due to oxidisable fat [5,13]. Moreover, the release
of cytokines in NASH causes accumulation of FFA
in the liver and the development of inflammatory
and necrotic changes [13]. Symptoms of NASH are
minor or absent. Occasionally, there is
hepatomegaly, increased activity of transaminase,
alkaline phosphatase, gamma glutamyl transpepti-
dase, serum transferrin saturation and ferritin
[1,31]. Diagnosis of NASH is established with the
liver biopsy when investigating a patient with ele-
vated transaminases [29,30]. Histological examina-
tion shows macrovesicular or microvesicular FL
and inflammation; Mallory bodies, fibrosis and cir-
rhosis may be present [1]. The treatment is
unknown. The beneficial effect is obtained by
body weight reduction, the attempts of the admin-
istration of ursodeoxycholic acid [29]. NASH fre-
quently remains not diagnosed, lasting for a long
time. This entity should always be considered in
the individual with otherwise unexplained raised
transaminases, whether or not they are diabetic or
obese. It may be a cause of so-called cryptogenic
liver cirrhosis diagnosed after several years of
asymptomatic course [1,29—31].
Symptoms, clinical course and diagnosis. There is
no difference between alcoholic and non-alcoholic
FL in terms of the clinical picture, biochemical tests
and histopathology of the liver [1,3,4,7].
Symptomatology and the clinical course of FL
depend on the severity of degenerative changes in
the liver, time-course of the etiologic factor affect-
ing the liver and possibility of its elimination.
Clinical features are not characteristic. The patient
is usually free of symptoms, may complain of right
upper quadrant discomfort or heaviness, some-
times have nausea or vomits, and in more severe
cases the deterioration of the general status with
the signs of hepatic failure is observed.
Examination of the patients shows usually the liver
smoothly enlarged with soft consistency and occa-
sional tenderness [1,3,4].
Uncomplicated and short lasting FL, e.g. after
short-term alcohol abuse or after ingestion of
drugs, is usually asymptomatic and without any
important changes in biochemical tests. FL lasting
for a long time (e.g. in obesity or diabetes mellitus)
causes slight enlargement of the liver, meteorism,
pain of the abdomen [1,3,4,7].
Severe dysfunction of the liver either from the nor-
mal status (e.g. in acute FL of pregnancy or after
hepatotoxic drugs), as well as in deterioration of
the already existing FL (e.g. acute viral infection in
the patient with diabetes or in alcohol drinkers),
may be presented with pain in the right upper
quadrant, jaundice, increased cholestitic enzymes
(alkaline phosphatase, gamma glutamyl transpepti-
dase) and transaminases, disturbances of the pro-
thrombin time, finally with the clinical symptoms
of hepatic failure [1,4,7].
Diagnosis of the FL is based on history, physical
examination and additional studies including bio-
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chemical tests, liver presentation in USG or CT,
and histological examination of the liver biopsy,
which is the most important diagnostic tool
[3,15,19,20,27,31,32]. Biochemical tests poorly
correlate with hepatic histology. Gamma glutamyl
transpeptidase is usually elevated, serum transami-
nases and alkaline phosphatase are usually normal
or slightly increased. FL is one of the most com-
mon causes of a raised serum transaminases activi-
ty detected in so-called Ôhealthy blood donorsÕ [1].
Careful analysis of the anamnesis in necessary. The
data concerning dietary habits, method of nutri-
tion, alcohol abuse, accompanying chronic dis-
eases, chronic abuse of drugs, metabolic and
endocrine disturbances (e.g. diabetes mellitus, thy-
roid diseases), malabsorption syndromes or degree
of circular and renal insufficiency are particularly
important [3,4,15].
FL may be suspected in patients with chronic alco-
holism, poorly controlled diabetes, obesity, hyper-
lipidaemia or malnutrition, in which the physical
examination shows enlarged liver or on the basis of
chronically observed slightly increased biochemical
tests assessing liver function [15,32—35]. However,
abnormal biochemical tests are seen only in
approx. 30—40% of cases with FL [15].
Diagnosis of FL may be frequently confirmed by
USG examination. Ultrasound may show bright
echo pattern of the enlarged liver, but can be nor-
mal as well. Spleen and portal vein system are also
normal [15,18,27,32,34]. In difficult cases, CT may
be performed and show a reduced attenuation,
which is less than that of the spleen or kidneys [1].
Magnetic resonance scanning is recently recom-
mended. It may detect fat infiltrations and allows
to assess it quantitatively [15,34,36]. The liver
biopsy is the best method of diagnosis [1,3,4]. It is
particularly useful when additional factors worsen
the prognosis of FL (cardiac failure, viral infection,
chronic treatment with drugs) or both clinical signs
and biochemical tests suggests possible activation
of inflammatory changes or development of the
liver cirrhosis.
Treatment. FL is potentially reversible and in the
majority of cases does not progress and does not
lead to the liver cirrhosis. The prognosis, however,
is bad in chronic alcoholics who continue drinking
as well as in acute toxic FL [7,14,15].
The main principle of FL treatment is based on the
elimination or minimisation of the etiologic factor
or the introduction of appropriate therapy of the
disease which caused FL. The following measures
are recommended: reasonable balanced diet in
obesity and in hyperlipidaemias, the discontinua-
tion of alcohol drinking and ingestion of hepato-
toxic drugs, proper dosage of insulin in diabetes
mellitus, balanced composition of TPN
[1,3,4,8,37]. Important elements of the FL therapy
include the dietetic treatment and chronic use of
pharmacological drugs properly selected against
the particular etiologic factor [37].
The diet in FL should be individually selected for
the patient, it should contain limited amount of
high-calorie and saturated lipids substances, the
optimal quantity of proteins, vitamins, particularly
from group B [3,4,38]. The supply of all necessary
aminoacids, including choline and methionine is
very important, too [23,24]. It was shown, that
both these aminoacids affect the metabolism of
membrane phospholipids and increase the export
of VLDL from the hepatocytes [23,24].
Some authors recommend the diet containing satu-
rated fatty acids (e.g. palm oil) in alcoholic FL [37].
It was observed that theses acids, through down-
regulation mechanism, decrease lipid peroxidation
in hepatocytes, which plays an important role in
the pathogenesis of alcoholic liver damage [2,37].
The pharmacotherapy with the so-called hepa-
totropic drugs or drugs which improve liver metab-
olism, is still controversial. Some authors recom-
mend therapy with Ôessential phospholipidsÕ (EPL;
[38,39]). Phospholipids are integral part of cell
membrane and play an important role in the
metabolism and oxidative processes [40]. During
the damage of hepatocytes, the damage of the
membranes takes place with release of phospho-
lipids [39,40]. Administration of the exogenous EPL
leads to the regeneration of membrane structure,
improving the metabolic function of the hepato-
cytes [39,40]. Some clinical studies showed signifi-
cant decrease of hepatic steatosis and the normali-
sation of the abnormal biochemical tests in patients
treated with EPL. It is believed that protective of
EPL on the hepatocyte membrane is based on the
decrease of lipid peroxidation, improvement of
membrane enzyme activity, diminution of steatosis
and necrotic lesions of hepatocytes and the
improvement of cell regeneration [40].
There are attempts to introduce the treatment of
FL with glutation based on the fact that it decreases
glutation concentration in hepatocytes, and it is
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responsible for the dysfunction in hepatic detoxifi-
cation processes [12]. Dentico et al. showed that
glutation administered in large quantities in FL
improved biochemical tests assessing the liver
damage [12].
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